Lisdexamfetamine dimesylate

Nature Reviews Drug Discovery

Volumn 6, Issue 5, 2007, Pages 343-344

  Elia, Josephine ^a   Easley, Chris ^b   Kirkpatrick, Peter ^c  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b IQVIA   (United States)

^c Nature Reviews Drug Discovery ^*

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; ATOMOXETINE; LISDEXAMFETAMINE; METHYLPHENIDATE; PLACEBO; PSYCHOSTIMULANT AGENT; UNCLASSIFIED DRUG; VYVANSE;

ARTICLE; ATTENTION DEFICIT DISORDER; BEHAVIOR CHANGE; BEHAVIOR THERAPY; CLINICAL TRIAL; COMORBIDITY; DRUG ABSORPTION; DRUG ABUSE; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDICATION; DRUG MISUSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; TREATMENT OUTCOME; UNITED STATES;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DEXTROAMPHETAMINE; DOPAMINE; DRUG APPROVAL; HUMANS; NOREPINEPHRINE; PRODRUGS; RANDOMIZED CONTROLLED TRIALS; SUBSTANCE-RELATED DISORDERS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 34247850975     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2315     Document Type: Article

References (15)

1. Elia, J. et al. Treatment of attention-deficit-hyperactivity disorder. N. Engl. J. Med. 340, 780-788 (1999).
2. Wilens, T. E. et al. Attention deficit/hyperactivity disorder across the lifespan. Ann. Rev. Med. 53, 113-131 (2002).
3. Kratochvil, C. J. et al. Atomoxetine: A selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder. Expert Opin. Pharmacother. 4, 1165-1174 (2003).
4. Solanto, M. V. Dopamine dysfunction in AD/HD: Integrating clinical and basic neuroscience research. Behav. Brain Res 130, 65-71 (2002)
5. Biederman, J. & Spencer, T. Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol. Psychiatry 46, 1234-1242 (1999).
6. Wilens, T. E. Mechanism of action of agents used in attention-deficit/ hyperactivity disorder. J. Clin. Psychiatry 67 (Suppl. 8), 32-38 (2006).
7. Food and Drug Administration. FDA labelling information [online], (2007).
8. Musser, C. J. et al. Stimulant use and the potential for abuse in Wisconsin as reported by school administrators and longitudinally followed children. J. Dev. Behav. Pediatr. 19, 187-192 (1998).
9. Poulin, C. Medical and nonmedical stimulant use among adolescents: From sanctioned to unsanctioned use. CMAJ 165, 1039-1044 (2001).
10. White, B. P. et al. Stimulant medication use, misuse, and abuse in an undergraduate and graduate student sample. J. Am. Coll. Health 54, 261-268 (2006).
11. Teter, C. J. et al. Illicit use of specific prescription stimulants among college students: Prevalence, motives, and routes of administration. Pharmacotherapy 26, 1501-1510 (2006).
12. Babcock, O. & Byrne, T. Student perceptions of methylphenidate abuse at a public liberal arts college. J. Am. Coll. Health 49, 143-145 (2000).
13. Ciccone, P. E. Attempted abuse of Concerta. J. Am. Acad. Child Adolesc. Psychiatry 41, 756 (2002).
14. Stefanatos, G. A. & Baron, I. S. Attention-deficit/hyperactivity disorder: A neuropsychological perspective towards DSM-V. Neuropsychol. Rev. 17, 5-38 (2007).
15. Fischer, M. & Barkley, R. A. Childhood stimulant treatment and risk for later substance abuse. J. Clin. Psychiatry 64, S11 19-23 (2003).